http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Bristol-Myers Squibb Reports First Quarter Financial Results
-
Trading Radar for 4/28: Ford (F), Aetna (AET), Twitter (TWTR), GoPro (GPRO), Panera Bread (PNRA) Report
-
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
-
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
-
First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma
-
CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
-
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America
-
Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.
-
Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases
-
Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28
-
Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases
-
Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3
-
Bristol-Myers Squibb's (BMY) Opdivo to Price at $12,500/Month - CNBC
-
Notable Analyst Rating Changes 05/15: (PLUG) (PTX) (TWTR) Upgraded; (BMY) (HII) (CXP) Downgraded
-
Trading Radar for 04/29: eBay (EBAY), Twitter (TWTR), Nokia (NOK), Express Scripts (ESRX), Seagate (STX) Report
-
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways
-
Notable Analyst Rating Changes 10/28: (BMY) (FTI) (PTEN) Upgraded; (LYG) (PEG) (BIDU) Downgraded

